Kananji Pharmaceutical Technology (Shanghai) Co., Ltd.

The main purpose is to evaluate the efficacy of CM082 tablets combined with everolimus, compared with everolimus alone or CM082 alone, in patients with metastatic renal cancer who have failed first-line VEGFR-TKI treatment. The safety of CM082 tablets and the safety of CM082 tablets combined with everolimus in the treatment of patients with renal cancer will be further evaluated.

Main study objectives: To observe the safety and tolerability of oral CM082 tablets combined with everolimus in the treatment of advanced renal clear cell carcinoma and determine the optimal dose of the combined drug. Secondary objectives: 1. To evaluate the preliminary efficacy of CM082 tablets combined with everolimus in the treatment of patients with advanced renal cancer. 2. To analyze the pharmacokinetics of CM082 combined with everolimus.

To evaluate the safety, tolerability, preliminary efficacy and pharmacokinetic characteristics of oral CM082 tablets (VEGFR/PDGFR dual inhibitor) in the treatment of wet age-related macular degeneration (wAMD), and to provide a safe and effective rational dosing regimen for Phase II clinical studies.